An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Inclusion Criteria:

• Newly diagnosed, histologically confirmed de novo acute myeloid leukemia (AML) orAML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML)

• Eastern cooperative oncology group performance status of 0, 1, or 2

• Has undergone induction therapy with intensive chemotherapy with or withoutconsolidation therapy

• Must have achieved first complete remission (CR) or complete remission withincomplete blood count recovery (CRi) status within 6 months (+/- 7 days) prior tostarting study therapy

Exclusion Criteria:

• Suspected or proven acute promyelocytic leukemia or acute myeloid leukemia withprevious hematologic disorder such as chronic myeloid leukemia or myeloproliferativeneoplasms, excluding myelodysplastic syndromes and chronic myelomonocytic leukemia

• Candidate for allogeneic bone marrow or stem cell transplant at screening

• Have achieved CR/CRi following therapy with hypomethylating agents

• AML associated with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) karyotypes ormolecular evidence of such translocations

• Proven central nervous system leukemia

• Prior bone marrow or stem cell transplantation

Other protocol-defined inclusion/exclusion criteria apply